TNF and rheumatoid arthritis: Although rapid development of cytokine-targeted therapeutic agents such as tumor necrosis factor (TNF) inhibitors has provided better clinical outcomes including achievement of remission for patients with RA, there are many unfavorable problems such as inadequate response, high cost, and adverse events such as infections [3, 4].